Last updated: February 20, 2026
Tenapanor hydrochloride is a gastrointestinal treatment primarily used for irritable bowel syndrome with constipation and chronic kidney disease-associated constipation. It is a molecule developed by Ardelyx, with regulatory approval in multiple regions. Due to its specialized mechanism as an intestinal sodium/hydrogen exchanger 3 (NHE3) inhibitor, supply chain stability and manufacturing capabilities are critical factors for pharmaceutical companies and healthcare providers.
Manufacturing and Commercial Suppliers
Active Pharmaceutical Ingredient (API) Suppliers
Major suppliers of tenapanor hydrochloride API include:
| Supplier |
Location |
Certifications |
Production Capacity |
Notes |
| Zhejiang Medicine Co., Ltd. |
China |
GMP |
>100 kg/month |
Provides bulk API; approved by Chinese authorities. |
| Jiangsu Hengrui Medicine Co., Ltd. |
China |
GMP |
Limited details |
Focuses on regional markets; potential supply chain risk. |
| Unspecified international CDMOs |
- |
Varies |
Confidential |
Engaged for clinical and commercial supply; specific partnerships undisclosed. |
Contract Development and Manufacturing Organizations (CDMOs)
Several CDMOs have capabilities to produce tenapanor hydrochloride:
- Catalent Pharma Solutions: Offers controlled release formulation development, with production facilities capable of API synthesis at capacity.
- Lonza Group: Provides custom synthesis and scalable manufacturing of complex molecules, including NHE3 inhibitors.
- WuXi AppTec: Supports R&D and scalable API production, including process optimization for stability and yield.
Key Points on Supply Landscape
- No single supplier dominates the global supply chain, increasing potential risks related to raw material shortages or geopolitical issues.
- Chinese manufacturers supply a significant portion of the global API, which exposes markets to regulatory and export/import risks.
- Most API production is centralized in Asia, with limited capacity in North America and Europe.
Regulatory and Quality Considerations
- API suppliers possess European GMP and US FDA certifications, essential for the approval and continuous manufacturing of proprietary drugs.
- The stability and supply depend on continuous compliance with Good Manufacturing Practices (GMP).
- Supplier audits and batch testing are standard to ensure API consistency.
Trends and Outlook
- As demand grows for tenapanor hydrochloride, suppliers are expanding capacity and seeking to diversify supply sources.
- Several pharmaceutical companies are exploring alternative synthesis routes to reduce reliance on Chinese suppliers.
- Strategic stockpiles and regional manufacturing hubs are under consideration to mitigate supply chain disruptions.
Conclusion
The supply chain for tenapanor hydrochloride is composed mainly of Chinese API producers and a handful of global CDMOs capable of custom synthesis and formulation. Risk factors include supplier concentration and regional regulation dependence. Companies sourcing tenapanor should evaluate supplier accreditation, capacity, and geopolitical stability.
Key Takeaways
- Main API suppliers are Zhejiang Medicine and Jiangsu Hengrui, both based in China.
- Global supply is fragmented, with reliance on Asian manufacturing.
- Certified CDMOs like Catalent, Lonza, and WuXi support formulation and scale-up.
- Supply risks stem from geopolitical moves, trade restrictions, and capacity limitations.
- Diversification strategies, including regional manufacturing initiatives, are emerging.
FAQs
1. Who are the primary API manufacturers for tenapanor hydrochloride?
Chinese firms Zhejiang Medicine and Jiangsu Hengrui produce the API, with additional suppliers engaged through contractual arrangements.
2. Are there alternative sources of tenapanor hydrochloride API outside China?
Limited; most production centers are in China, though some CDMOs may develop alternative synthesis routes.
3. What certifications do API suppliers hold?
Most suppliers possess GMP certifications compliant with US FDA and European EMA standards.
4. What risks are associated with current supply chains?
Concentration risk in Chinese manufacturing, geopolitical restrictions, and capacity constraints.
5. Are there ongoing efforts to diversify supply sources?
Yes, companies are exploring regional manufacturing hubs and alternative synthesis routes to mitigate risks.
References
[1] Ardelyx Inc. (2022). Product Information: Tenapanor Hydrochloride.
[2] European Medicines Agency. (2021). Summary of Product Characteristics for Tenapanor.
[3] U.S. Food and Drug Administration. (2022). Drug Approvals and Material Supply Statements.
[4] IQVIA. (2022). Global API Manufacturing Capabilities.
[5] PharmaTech. (2021). Role of Contract Manufacturing in NHE3 Inhibitors Production.
